ROCKLAND, Mass.--(BUSINESS WIRE)--Oct 16, 2023--EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany in the US and Canada, today announced that 28 abstracts featuring the latest research on the company鈥檚 oncology portfolio addressing unmet needs across bladder, head and neck, ...
RAHWAY, N.J.--(BUSINESS WIRE)--Oct 16, 2023--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved KEYTRUDA, Merck鈥檚 anti-PD-1 therapy, as a monotherapy for the adjuvant treatment of adults with non-small cell ...
ATLANTA--(BUSINESS WIRE)--Oct 16, 2023--<a ...
CARDIFF, Wales & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct 16, 2023--Antiverse Ltd (Antiverse), a biotechnology company developing a computational antibody drug discovery platform, and GlobalBio, Inc. (GlobalBio), an antibody engineering company developing methods to engineer improved ...
ROCKLAND, Mass.--(BUSINESS WIRE)--Oct 16, 2023--EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany in the US and Canada, today announced that 28 abstracts featuring the latest research on the company鈥檚 oncology portfolio addressing unmet needs across bladder, head and neck, ...
NANTES, France--(BUSINESS WIRE)--Oct 16, 2023--Regulatory News:<em>OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE)</em> presented the first Phase 1/2 positive clinical results with high affinity anti-PD1 monoclonal antibody OSE-279 in advanced solid tumors ...